Genetic Technologies Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin Camilleri
- Full Time Employees
- 55
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 60-66 Hanover Street Fitzroy VIC Australia 3065
- IPO Date
- Sep 6, 2005
- CIK
- 0001166272
- Website
- gtglabs.com
- Similar Companies
- Business
- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE), founded in 1987 and headquartered in Prahran, Australia, is a molecular diagnostics company that develops and commercializes predictive genetic testing and risk assessment tools; its core offerings include the BREVAGeneplus test for non-hereditary breast cancer risk, geneType portfolio multi-risk assessments for diseases such as colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease, type 2 diabetes, pancreatic cancer, melanoma and atrial fibrillation, and genetic testing services encompassing medical, animal, forensic and plant testing through EasyDNA and AffinityDNA brands. The company operates in the Americas, Canada, Europe, the Middle East, Africa, Latin America and the Asia Pacific, targeting physicians, healthcare professionals, obstetricians, gynecologists and breast cancer specialists with its clinically validated, non-invasive saliva-based tests that integrate genomic and clinical data for personalized health management. In recent developments, Genetic Technologies completed the sale of its AffinityDNA and EasyDNA direct-to-consumer businesses to Endeavor DNA, Inc. in January 2025 and sold its geneType business and assets to Rhythm Biosciences Limited in December 2024; it executed binding term sheets in June 2025 for the strategic acquisitions of Ellerfield Wealth Pty Ltd and Walker Capital Private Wealth Pty Ltd for A$7 million in shares to pivot into diversified financial services and wealth management; additionally, the company implemented a capital-light operating model restructure in 2024, reducing monthly cash burn from A$800,000 to under A$200,000, launched geneType globally on the EasyDNA platform across 42 countries, expanded into Canada and New Zealand, secured B2B partnerships such as with Wellworks for U.S. employer groups, and appointed Jules Grove as Chief Financial Officer effective May 2025 while transitioning CEO Simon Morriss.
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
M/I HOMES ANNOUNCES ELECTION OF GENE SMITH TO BOARD OF DIRECTORS
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy
Genetic variations linked to weight loss, side effects from GLP-1 drugs
New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects
From Genetic Puzzle to Industrial Platform
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies